Dana-Farber Aug 18, 2022 Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change Premium Jul 6, 2022 Structural Variant Study Points to Pediatric Glioma Drivers, Prognostic Features Jun 24, 2022 Molecular Tumor Profiling Benefits Pediatric Cancer Patients, Study Finds Jun 8, 2022 New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur Premium Jun 2, 2022 Stand Up To Cancer, Mirati Fund Research into KRAS G12C Inhibitor Resistance Premium May 12, 2022 ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making Premium Apr 28, 2022 Reveal Genomics, Dana-Farber Using HER2DX to Analyze Data in Three Breast Cancer Trials Feb 7, 2022 Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute Nov 12, 2021 In Brief This Week: AstraZeneca, CytoDyn, BerGenBio, Bayer, Dana-Farber Cancer Institute, Kronos Bio Oct 20, 2021 SpringWorks Therapeutics Licenses EGFR Inhibitors From Dana-Farber, Inks Two R&D Partnerships Oct 12, 2021 MIT Spinoff Travera Looks to Validate Cell Mass as Broadly Predictive Cancer Biomarker Premium Aug 23, 2021 Broad Institute, Dana-Farber Open Enrollment in Cancer Research Project to All US, Canadian Patients Jul 2, 2021 In Brief This Week: Syndax, Transgene, Sermonix, AccessHope, Achilles, Foundation Medicine Jun 24, 2021 Researchers Make Progress in Characterizing Diverse Mechanisms of KRAS Inhibitor Resistance Premium May 12, 2021 Dana-Farber Cancer Institute Receives $50M Gift to Advance Pancreatic Cancer Research Mar 3, 2021 Nonprofit Count Me In to Return Genomic Results to Patients With Rare Cancers Premium Feb 19, 2021 In Brief This Week: AstraZeneca, Merck, Amgen, Kintara Therapeutics, Dana Farber Cancer Institute Jan 22, 2021 MMRF, Dana Farber Amassing Data to Develop Smoldering Multiple Myeloma Monitoring Test Premium Dec 3, 2020 MMRF, Dana Farber Partner on Search for Biomarkers Linked to Smoldering Multiple Myeloma Progression Aug 10, 2020 T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma Load More Breaking News In Brief This Week: Gilead Sciences, Arcus Biosciences, Verismo Therapeutics, Caris Life Sciences Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round
